Professor of Anesthesia, Harvard Medical School
Vice Chair of Faculty Affairs, Department of Anesthesia, Critical Care & Pain Medicine, BIDMC
meikerma@bidmc.harvard.edu
617-754-2721

Back to Anesthesia Research

Dr. Eikermann has the vision of improving postoperative patient outcomes based on an individualized treatment approach. Outcomes that matter to daily living and quality of life after surgery and critical care are addressed in his research through three complementary approaches:

  1. The investigation of highly granular pharmaco-physiological patient data to understand the effects of new treatments in vulnerable patients recovering from surgery. Dr. Eikermann and his team analyze the effects of low-dose Ketamine infusion on respiratory stimulation and transpulmonary pressure in ventilated ICU patients with the aim of identifying treatment approaches facilitating extubation readiness. 
  2. The utilization of meticulously generated electronic data bases to focus on the effects of various patient characteristics and intraoperative factors on postoperative outcomes. The wide range of endpoints of interest includes clinical outcomes, health-care utilization (e.g. 30-day readmission) as well as long-term outcomes, such as mortality and functional independence. A current major focus of Dr. Eikermann’s research group is the identification of surgical patients at increased risk of ischemic stroke after surgery. In 2017 and 2018, his team has published three papers characterizing migraine and a patent foramen ovale as risk factors of ischemic stroke in patients undergoing surgery. Postoperative respiratory complications represent a further clinically meaningful endpoint of interest. Dr. Eikermann’s team has shown various anesthesia-related factors to be associated with adverse respiratory outcomes, such as the intraoperative use of intermediate acting neuromuscular blocking agents. 
  3. The conduct of prospective clinical studies to verify and improve effectiveness and implementability of treatment strategies identified as promising in retrospective studies. Dr. Eikermann’s team is currently evaluating the effects of mobilization dose on discharge disposition in critically ill stroke patients, as part of a multi-center, international study conducted at BIDMC, MGH, Italian, and German centers – a follow-up study of the “SOMS” trial published in 2016. In this multicenter, international, randomized, placebo-controlled “MIDAS” trial, Dr. Eikerman´s team investigated the efficacy of Midodrine treatment for refractory hypotension in critically ill patients and investigated duration of vasopressor treatment and ICU length of stay endpoints.

About Matthias Eikermann

Dr. Matthias Eikermann is a Professor of Anaesthesia at Harvard Medical School, attending anesthesiologist and Vice Chair of Faculty Affairs in the Department of Anesthesia, Critical Care and Pain Medicine at BIDMC. Dr. Eikermann obtained his medical training at Heinrich-Heine-Universität in Düsseldorf, Germany, and his Ph.D in Anesthesiology From the Essen-Duisburg University in Essen, Germany. As an internationally-renowned clinical and outcomes researcher, Dr. Eikermann is leading his own lab of postdoctoral research fellows and students at BIDMC, providing a broad field of research opportunities for BIDMC residents, fellows and faculty.